.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

'Cutting edge' nonmelanoma research branches three ways

November 1, 2001

Dallas - Activation of the immune system may prove to be an importanttherapeutic adjuvant in the treatment of nonmelanoma skin cancers in difficultto treat regions, in those that have a high potential to recur, or in individualsfor whom surgery is not possible, Russell P. Hall, III, M.D., said at theannual meeting of the American College of Mohs Micrographic Surgery andCutaneous Oncology.